We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EPAM:NYSEEPAM Systems, Inc. Analysis

Data as of 2026-07-17 - not real-time

$87.67

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

EPAM is trading above its short‑term moving average but remains under its mid‑term benchmark, signaling a short‑term pullback within a longer bearish framework. The RSI hovers around the neutral midpoint and the MACD has turned bullish, offering a modest technical upside despite decreasing volume and elevated recent volatility. Fundamentally, the stock’s price‑to‑earnings multiple sits comfortably below the sector average and the discounted cash‑flow model implies a substantial upside potential, while the balance sheet shows ample cash and modest debt. Recent accolades—including the Databricks AI Partner of the Year award—and a strategic AI collaboration with TGS reinforce the company’s growth narrative in high‑margin cloud and analytics services.
Overall, the blend of a resilient earnings outlook, attractive valuation relative to peers, and emerging AI‑focused initiatives supports a positive medium‑to‑long‑term thesis, though the current technical bearish bias and softening volume suggest a cautious short‑term stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Technical bias remains bearish with price below mid‑term average
  • Volume trend is weakening, indicating limited near‑term buying pressure
  • Upcoming earnings could clarify momentum

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • AI partnership and Databricks recognition expand high‑growth opportunities
  • Valuation metrics suggest significant upside versus intrinsic value
  • Strong cash position and low leverage support continued investment

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Secular demand for digital platform engineering and AI services
  • Consistent revenue growth and improving profitability margins
  • Undervalued pricing relative to long‑term cash‑flow projections

Key Metrics & Analysis

Financial Health

Revenue Growth7.60%
Profit Margin6.96%
P/E Ratio12.3
ROE10.93%
ROA8.05%
Debt/Equity8.39
P/B Ratio1.3
Op. Cash Flow$594.4M
Free Cash Flow$692.9M
Industry P/E33.2

Technical Analysis

TrendBearish
RSI49.4
Support$73.06
Resistance$94.27
MA 20$83.23
MA 50$92.62
MA 200$148.24
MACDBullish
VolumeDecreasing
Fear & Greed Index91.55

Valuation

Fair Value$253.46
Target Price$135.94
Upside/Downside55.06%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.67
Volatility61.16%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.